New Delhi: Drug firm Zydus Cadila on Wednesday said it has received approval from the US health regulator to market diabetes drug, Empagliflozin and Linagliptin tablets, in the US market. The company has received tentative approval from the US Food and Drug Administration (USFDA) to market its generic product, Zydus Cadila said in a statement.
The company has received approval for the product in the strengths of 10 mg/5 mg and 25 mg/5 mg, it added. This medication contains a combination of Empagliflozin and Linagliptin, oral diabetes medicines that help control blood sugar levels.
Also read: Dr Reddy’s Lab launches Fulvestrant Inj
The drug is used together with diet and exercise to improve blood sugar control in adults with type 2 diabetes mellitus. Zydus said the drug will be manufactured at the group’s formulation manufacturing facility at SEZ, Ahmedabad.
The group now has 299 approvals and has so far filed over 390 abbreviated new drug applications (ANDAs) since the commencement of filing process in 2003-04, it added.
The Health Master is now on Telegram. For latest update on health and Pharmaceuticals, subscribe to The Health Master on Telegram.
